Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Takeda Pharmaceutical Co Ltd (JP:4502)
:4502
Holding JP:4502?
Track your performance easily
Earnings Data
Report Date
Jan 30, 2025TBA Not Confirmed
Period Ending
2024 (Q3)Consensus EPS Forecast
26.2Last Year’s EPS
67.59Same Quarter Last Year
Moderate Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 31, 2018
|% Change Since: 0.00%
|Next Earnings Date:Jul 31, 2018
Earnings Call Sentiment|Neutral
The earnings call reflects a mixed performance with strong growth in new products and strategic pipeline advancements, countered by significant challenges from loss of exclusivity and impairment losses. While the company is confident in its long-term strategy and financial resilience, current fiscal challenges weigh heavily.Company Guidance
During Takeda's Q3 2023 earnings call, the company reported key financial metrics and provided guidance for the remainder of the fiscal year. Takeda's top-line growth was driven by its growth and launch products, which now comprise 43% of total revenue and grew by 12.7% at constant exchange rates. Despite facing significant loss of exclusivity impacts, notably from VYVANSE in the U.S. and AZILVA in Japan, the company's core revenue remained flat year-to-date at JPY 3.2 trillion. The core operating profit was JPY 865.6 billion, reflecting a 12.7% decline at constant exchange rates due to generic competition and increased R&D investments. Takeda remains confident in its pipeline, highlighted by U.S. approvals of FRUZAQLA and ADZYNMA, and anticipates exceeding JPY 1 trillion in core operating profit for the full year. The company maintains its guidance for low single-digit percentage declines in revenue and core operating profit at constant exchange rates for FY 2023, with a free cash flow forecast of JPY 400 to 500 billion.Strong Growth in Launch Products
Growth and launch products now represent 43% of total revenue and grew by 12.7% at constant exchange rate.
Pipeline Advancements
Two new molecules, FRUZAQLA and ADZYNMA, approved in the U.S., marking significant milestones in oncology and rare disease treatment.
ENTYVIO and Qdenga Performance
ENTYVIO is the most prescribed treatment for IBD with 7% revenue growth, and Qdenga launched in 21 countries with strong initial demand.
Financial Resilience
Despite challenges, Takeda is on track to exceed JPY 1 trillion in core operating profit for the year, with strong cash generation and debt management.
---
JP:4502 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
JP:4502 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Jan 30, 2025 | ¥4153.00 | ¥4180.00 | +0.65% |
| Oct 31, 2024 | ¥4251.00 | ¥4264.00 | +0.31% |
| Jul 31, 2024 | ¥4147.00 | ¥4202.68 | +1.34% |
| May 09, 2024 | ¥3959.43 | ¥3976.04 | +0.42% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Takeda Pharmaceutical Co Ltd (JP:4502) report earnings?
Takeda Pharmaceutical Co Ltd (JP:4502) is schdueled to report earning on Jan 30, 2025, TBA Not Confirmed.
What is Takeda Pharmaceutical Co Ltd (JP:4502) earnings time?
Takeda Pharmaceutical Co Ltd (JP:4502) earnings time is at Jan 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Takeda Pharmaceutical Co Ltd stock?
The P/E ratio of Takeda Pharmaceutical Co is N/A.
What is JP:4502 EPS forecast?
JP:4502 EPS forecast for the fiscal quarter 2024 (Q3) is 26.2.
---